These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
72 related articles for article (PubMed ID: 22552265)
41. Pharmacokinetics and safety of AZD9668, an oral neutrophil elastase inhibitor, in healthy volunteers and patients with COPD. Gunawardena KA; Gullstrand H; Perrett J Int J Clin Pharmacol Ther; 2013 Apr; 51(4):288-304. PubMed ID: 23391369 [TBL] [Abstract][Full Text] [Related]
42. Pharmacokinetics, safety and tolerability of pirfenidone and its major metabolite after single and multiple oral doses in healthy Chinese subjects under fed conditions. Huang NY; Ding L; Wang J; Zhang QY; Liu X; Lin HD; Hua WY Drug Res (Stuttg); 2013 Aug; 63(8):388-95. PubMed ID: 23580109 [TBL] [Abstract][Full Text] [Related]
43. Clinical pharmacology of the dual orexin receptor antagonist ACT-541468 in elderly subjects: Exploration of pharmacokinetics, pharmacodynamics and tolerability following single-dose morning and repeated-dose evening administration. Muehlan C; Boehler M; Brooks S; Zuiker R; van Gerven J; Dingemanse J J Psychopharmacol; 2020 Mar; 34(3):326-335. PubMed ID: 31642731 [TBL] [Abstract][Full Text] [Related]
44. Pharmacokinetic and pharmacodynamic characterisation of JNJ-40411813, a positive allosteric modulator of mGluR2, in two randomised, double-blind phase-I studies. Salih H; Anghelescu I; Kezic I; Sinha V; Hoeben E; Van Nueten L; De Smedt H; De Boer P J Psychopharmacol; 2015 Apr; 29(4):414-25. PubMed ID: 25735992 [TBL] [Abstract][Full Text] [Related]
45. The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers. Shi JG; Chen X; Lee F; Emm T; Scherle PA; Lo Y; Punwani N; Williams WV; Yeleswaram S J Clin Pharmacol; 2014 Dec; 54(12):1354-61. PubMed ID: 24965573 [TBL] [Abstract][Full Text] [Related]
46. Pharmacokinetics, pharmacodynamics and safety of CEP-26401, a high-affinity histamine-3 receptor antagonist, following single and multiple dosing in healthy subjects. Spiegelstein O; Stevens J; Van Gerven J; Nathan PJ; Maynard JP; Mayleben DW; Hellriegel E; Yang R J Psychopharmacol; 2016 Oct; 30(10):983-93. PubMed ID: 27222271 [TBL] [Abstract][Full Text] [Related]
47. Clinical Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Darexaban, an Oral Direct Factor Xa Inhibitor, in Healthy Elderly Japanese Subjects. Kadokura T; Oikawa K; Miyata K; Murase T; Nakamura M Clin Pharmacol Drug Dev; 2013 Oct; 2(4):328-35. PubMed ID: 27121937 [TBL] [Abstract][Full Text] [Related]
48. Apixaban pharmacodynamic activity in umbilical cord, paediatric, and adult plasma. Yetman RJ; Barrett YC; Wang Z; Adamczyk R; Wang J; Ramacciotti E; Frost C Thromb Haemost; 2017 Jul; 117(8):1518-1527. PubMed ID: 28536722 [TBL] [Abstract][Full Text] [Related]
49. Pharmacokinetics, Safety, Tolerability, and Pharmacodynamics of Alicapistat, a Selective Inhibitor of Human Calpains 1 and 2 for the Treatment of Alzheimer Disease: An Overview of Phase 1 Studies. Lon HK; Mendonca N; Goss S; Othman AA; Locke C; Jin Z; Rendenbach-Mueller B Clin Pharmacol Drug Dev; 2019 Apr; 8(3):290-303. PubMed ID: 30052328 [TBL] [Abstract][Full Text] [Related]
50. A randomized, placebo-controlled study of the pharmacokinetics, pharmacodynamics, and tolerability of the oral JAK2 inhibitor fedratinib (SAR302503) in healthy volunteers. Zhang M; Xu CR; Shamiyeh E; Liu F; Yin JY; von Moltke LL; Smith WB J Clin Pharmacol; 2014 Apr; 54(4):415-21. PubMed ID: 24165976 [TBL] [Abstract][Full Text] [Related]
51. First-in-human trial of SAR107375E, a novel small molecule anticoagulant with dual inhibition of factor Xa and factor IIa. Wu S; Wang T; Li J; Zhang Z; Li C; Xiao S; He J; Wang X; Hu Z; Wang X; Zheng S; Liang X; Chen G; Li Y; Li X; Zhan Y; Zou Q; Jiang H; Zheng Q; Ban L; Liu H; Fang Y Expert Opin Investig Drugs; 2023; 32(11):1085-1094. PubMed ID: 37955047 [TBL] [Abstract][Full Text] [Related]
52. Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Intravenous Dose of Miridesap in Healthy Japanese Subjects. Ino H; Doi Y; Liefaard L; Cookson L; Chen C; Itoh H; Igarashi H; Nakano A Clin Pharmacol Drug Dev; 2019 Jul; 8(5):612-618. PubMed ID: 30556959 [TBL] [Abstract][Full Text] [Related]
53. Safety, pharmacokinetics, and reversal of apixaban anticoagulation with andexanet alfa. Siegal D; Lu G; Leeds JM; Karbarz M; Castillo J; Mathur V; Hutchaleelaha A; Sinha U; Kitt M; McClure M; Hollenbach SJ; Curnutte JT; Conley PB; Crowther M Blood Adv; 2017 Sep; 1(21):1827-1838. PubMed ID: 29296829 [TBL] [Abstract][Full Text] [Related]
54. Pharmacokinetics and safety of an antirhinoviral agent, ruprintrivir, in healthy volunteers. Hsyu PH; Pithavala YK; Gersten M; Penning CA; Kerr BM Antimicrob Agents Chemother; 2002 Feb; 46(2):392-7. PubMed ID: 11796347 [TBL] [Abstract][Full Text] [Related]
55. Oxiracetam pharmacokinetics following single and multiple dose administration in the elderly. Perucca E; Parini J; Albrici A; Visconti M; Ferrero E Eur J Drug Metab Pharmacokinet; 1987; 12(2):145-8. PubMed ID: 3691580 [TBL] [Abstract][Full Text] [Related]
56. Pharmacokinetics and pharmacodynamics of the cathepsin S inhibitor, LY3000328, in healthy subjects. Payne CD; Deeg MA; Chan M; Tan LH; LaBell ES; Shen T; DeBrota DJ Br J Clin Pharmacol; 2014 Dec; 78(6):1334-42. PubMed ID: 25039273 [TBL] [Abstract][Full Text] [Related]
57. Pharmacodynamics and Pharmacokinetics of oral factor Xa inhibitors. Persson PB Clin Pharmacol; 2015; 7():77-8. PubMed ID: 26005360 [No Abstract] [Full Text] [Related]
58. Pharmacokinetics and pharmacodynamics in adolescents. January 20-21, 1994. Proceedings. J Adolesc Health; 1994 Dec; 15(8):605-78. PubMed ID: 7696278 [No Abstract] [Full Text] [Related]
59. Correction: First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer. Clin Cancer Res; 2015 Feb; 21(3):660. PubMed ID: 25646183 [No Abstract] [Full Text] [Related]
60. Safety, pharmacokinetics and pharmacodynamics of multiple ascending doses of R1663, an oral factor Xa inhibitor, in healthy young subjects coupled with exploration of influence of gender and age. Schmitt C; Charoin-Pannier A; McIntyre C; Zandt H; Ciorciaro C; Winters K; Pepper T Thromb Haemost; 2012 Jul; 108(1):54-64. PubMed ID: 22552265 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]